Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc
Total Receivables
Brainstorm Cell Therapeutics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
Total Receivables
$67k
|
CAGR 3-Years
4%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$5.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
20%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Brainstorm Cell Therapeutics Inc
Glance View
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
See Also
What is Brainstorm Cell Therapeutics Inc's Total Receivables?
Total Receivables
67k
USD
Based on the financial report for Mar 31, 2025, Brainstorm Cell Therapeutics Inc's Total Receivables amounts to 67k USD.
What is Brainstorm Cell Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
-21%
Over the last year, the Total Receivables growth was 158%. The average annual Total Receivables growth rates for Brainstorm Cell Therapeutics Inc have been 4% over the past three years , -31% over the past five years , and -21% over the past ten years .
